David Paul Keenan
Known title: EVP, Chief Operating OfficerCIK: 0002094574
Associated companies
Transaction History
| AMRN | ▲ Buy | Option Exercise | 3,688 | — | 7/1/2026 | View on chart |
| AMRN | ▼ Sell | Tax Withholding | 1,926 | $31K | 7/1/2026 | View on chart |
| AMRN | ▲ Buy | Option Exercise | 2,246 | — | 1/31/2026 | View on chart |
| AMRN | ▼ Sell | Tax Withholding | 1,173 | $18K | 1/31/2026 | View on chart |
| AMRN | ▲ Buy | Option Exercise | 1,933 | — | 1/31/2026 | View on chart |
| AMRN | ▼ Sell | Tax Withholding | 1,010 | $16K | 1/31/2026 | View on chart |
| AMRN | ▲ Buy | Option Exercise | 3,688 | — | 1/2/2026 | View on chart |
| AMRN | ▼ Sell | Tax Withholding | 1,926 | $27K | 1/2/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Amarin (AMRN) sees competition as Teva pushes branded drugs
Teva Pharmaceutical announced that branded drugs will be a central part of its growth plan. This focus highlights the competitive environment for other companies with specialty branded products, such as Amarin’s Vascepa. The news may influence market perception of Amarin’s positioning within the branded drug space.
Amarin (AMRN) sees competition as Teva pushes branded drugs. Teva Pharmaceutical announced that branded drugs will be a central part of its growth plan. This focus highlights the competitive environment for other companies with specialty branded products, such as Amarin’s Vascepa. The news may influence market perception of Amarin’s positioning within the branded drug space.